References
- Shao W, Li X, Goraya MU, et al. Evolution of Influenza A virus by mutation and re-assortment. Int J Mol Sci. 2017 Aug;18(8):E1650.
- Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):47–60.
- Weis W, Brown JH, Cusack S, et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988 Jun;333(6172):426–431.
- Thyagarajan B, Bloom JD. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife. 2014 Jul;3:e03300.
- Lee PS, Wilson IA. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol. 2015;386:323–341.
- Allen JD, Ross TM. H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018;14(8):1840–1847.
- Koel BF, Burke DF, Bestebroer TM, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013 Nov;342(6161):976–979.
- Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 08;16(8):942–951.
- Parker L, Wharton SA, Martin SR, et al. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol. 2016 06;97(6):1333–1344.
- Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.
- Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017 Oct;13(10):e1006682.
- Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017 11;114(47):12578–12583.
- Perdue ML, Arnold F, Li S, et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines. 2011 Aug;10(8):1183–1194.
- Barr IG, Donis RO, Katz JM, et al. Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:44.
- Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. Clin Infect Dis. 2019 Oct 30;69(10):1817–1823.
- Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses. 2008 Nov;2(6):211–219.
- Rondy M, Gherasim A, Casado I, et al. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. Euro Surveill. 2017 Oct;22(41):17–00645.
- Kissling E, Rondy M, I-MOVE/I-MOVE+ STUDY TEAM. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe, Euro Surveill, 2017;22(7):30464.
- Ministero della Salute - Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2017–2018. [cited 2019 Oct 25]. Available from: http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2017&codLeg=60180&parte=1%20&serie=null
- Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases (NCIRD). Virology, surveillance, and diagnosis branch. [cited 2019 Oct 25]. Available from: https://www.cdc.gov/ncird/flu.html
- Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009 Oct;83(19):10309–10313.
- WHO. Global influenza surveillance network. Manual for the laboratory diagnosis and virological surveillance of influenza. [cited 2019 Oct 25]. Available from: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
- Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95–98.
- GenBank. NCBI - NIH. [cited 2019 Oct 25]. Available from: https://www.ncbi.nlm.nih.gov/genbank/
- Tamura K, Stecher G, Peterson D, et al. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013 Dec;30(12):2725–2729.
- GISAID - Global Initiative on Sharing All Influenza Data. [cited 2019 Oct 25]. Available from: platform.gisaid.org/epi3/
- Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985 Jul;39(4):783–791.
- Lindstrom S, Sugita S, Endo A, et al. Evolutionary characterization of recent human H3N2 influenza A isolates from Japan and China: novel changes in the receptor binding domain. Arch Virol. 1996;141(7):1349–1355.
- Muñoz ET, Deem MW. Epitope analysis for influenza vaccine design. Vaccine. 2005 Jan;23(9):1144–1148.
- Yang H, Carney PJ, Chang JC, et al. Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins. Virology. 2015;477:18–31.
- Gupta R, Jung E, Brunak S Prediction of N-glycosylation sites in human proteins. 2004. [cited 2019 Oct 25]. Available from: http://www.cbs.dtu.dk/services/NetNGlyc/
- Bonomo ME, Deem MW. Predicting influenza H3N2 vaccine efficacy from evolution of the dominant epitope. Clin Infect Dis. 2018 Sep;67(7):1129–1131.
- Gupta V, Earl DJ, Deem MW. Quantifying influenza vaccine efficacy and antigenic distance. Vaccine. 2006 May;24(18):3881–3888.
- The Francis Crick Institute - Worldwide Influenza Centre. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2016–2017. 22nd – 24th February 2016. [cited 2019 Oct 25]. Available from: https://www.crick.ac.uk/sites/default/files/2018-07/crick_feb2016_vcm_report_to_post.pdf
- Lee HK, Tang JW, Kong DH, et al. Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One. 2013;8(11):e79252.
- Nakowitsch S, Waltenberger AM, Wressnigg N, et al. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. Biotechnol J. 2014 Mar;9(3):405–414.
- European Centre for Disease Prevention and Control (ECDC). Types of seasonal influenza vaccine. [cited 2019 Oct 25]. Available from: https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine
- U.S. Food & Drug Administration (FDA). [cited 2019 Oct 25]. Available from: https://www.fda.gov.
- Flannery B, Chung JR, Monto AS, et al. Influenza vaccine effectiveness in the United States during the 2016–2017 season. Clin Infect Dis. 2019 May;68(11):1798–1806.
- Manini I, Trombetta CM, Lazzeri G, et al. Egg-independent influenza vaccines and vaccine candidates. Vaccines (Basel). 2017 Jul;5(3):E18.
- Lamb YN. Cell-based quadrivalent inactivated influenza virus vaccine (Flucelvax). Drugs. 2019 Aug;79(12):1337–1348.
- Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017–18. J Infect Dis. 2019 July 1;220(1):179–188.